Endothelial Nitric Oxide Synthase T-786C Mutation, Prothrombin Gene Mutation (G-20210-A) and Protein S Deficiency Could Lead to Myocardial Infarction in a Very Young Male Adult
DOI:
https://doi.org/10.3889/oamjms.2016.014Keywords:
(eNOS) T-786C mutation, prothrombin gene mutation (G-20210-A), protein S deficiency, myocardial infarction, young maleAbstract
INTRODUCTION: Myocardial infarction is a rare medical event in young people. The main reasons include congenital coronary abnormalities, coronary artery spasm, and coronary thrombosis due to hypercoagulable states (hereditary and acquired).
AIM: We present a case of a young male adult with myocardial infarction caused by a combination of gene mutations and anticoagulation protein deficiency.
CASE PRESENTATION: A 19 years old young man was admitted to our hospital complaining of chest pain during the last two weeks. The patient did not have any known cardiovascular risk factors, except a positive family anamnesis. Subacute inferior nonST segment myocardial infarction was diagnosed according to the patient’s history, electrocardiographic and laboratory findings. Coronary angiography revealed suboclusive thrombus in the proximal, medial and distal part of the right coronary artery (TIMI 2). Percutaneous coronary intervention was performed. Anticoagulant and antiagregant therapy (heparin, acetilsalicilic acid and clopidogrel) according to protocol was started. The hospital stay was uneventful. Homozygous endothelial nitric oxid synthase (eNOS) T-786-C mutation, heterozygote prothrombin gene mutation (G-20210-A), and protein S deficiency were verified from the thrombophilia testing. Other trombophilic tests were normal. Three months after discharge from hospital another coronary angiography was performed. It revealed normal coronary arteries. Four years after the attack, the patient is free of symptoms and another cardiovascular event.
CONCLUSION: Combination of genetic mutations and anticoagulation protein deficiency could be a reasonable cause for myocardial infarction in a very young male adult without any other cardiovascular risk factors.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998;97(11):1037.
http://dx.doi.org/10.1161/01.CIR.97.11.1037 DOI: https://doi.org/10.1161/01.CIR.97.11.1037
PMid:9531249
Guilland JC, Favier A, Potier de Courcy G, Galan P, et al. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? Pathol Biol. 2003;51(2):101-10.
http://dx.doi.org/10.1016/S0369-8114(03)00104-4 DOI: https://doi.org/10.1016/S0369-8114(03)00104-4
Muniz Caldas CA, Freire de Carvalho J. Cardiovascular comorbidities in antiphospholipid syndrome. Expert Rev Clin Immunol. 2013;9(10):987-90.
http://dx.doi.org/10.1586/1744666X.2013.837261 DOI: https://doi.org/10.1586/1744666X.2013.837261
PMid:24128160
Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa. 2008;37(1):19-30.
http://dx.doi.org/10.1024/0301-1526.37.1.19 DOI: https://doi.org/10.1024/0301-1526.37.1.19
PMid:18512539
Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146(6):948-57.
http://dx.doi.org/10.1016/S0002-8703(03)00519-2 DOI: https://doi.org/10.1016/S0002-8703(03)00519-2
Lalouschek W, Schillinger M, Hsieh K, et al. Matched case-control study on factor V and the prothrombin G20210A mutation in patients with ischemic stroke/transient ishemic attack up to age of 60 years. Stroke. 2005;36(7):1405.
http://dx.doi.org/10.1161/01.STR.0000170635.45745.b8 DOI: https://doi.org/10.1161/01.STR.0000170635.45745.b8
PMid:15947254
Reitsma P.H., Rosendaal F.R. Past and future of genetic research in thrombosis. J Thromb Haemost. 2007;5(Suppl 1):264-9.
http://dx.doi.org/10.1111/j.1538-7836.2007.02502.x DOI: https://doi.org/10.1111/j.1538-7836.2007.02502.x
PMid:17635735
Mark Y. Chan, Felicita A., Richard B. Hypercoagulable States in Cardiovascular Disease. Circulation. 2008;118:2286-2297.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.778837 DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.778837
PMid:19029477
ESC guidelines for the Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation. European Heart Journal. 2011;32:2999–3054.
http://dx.doi.org/10.1093/eurheartj/ehr236 DOI: https://doi.org/10.1093/eurheartj/ehr236
PMid:21873419
Toda N, Tanabe S, Nakanishi S. Nitric oxide-mediated coronary flow regulation in patients with coronary artery disease: recent advances. Int J Angiol. 2011;20(3):121-34.
http://dx.doi.org/10.1055/s-0031-1283220 DOI: https://doi.org/10.1055/s-0031-1283220
PMid:22942627 PMCid:PMC3331658
Glueck CJ, Valdes A, Bowe D, Munsif S, et al. The endothelial nitric oxide synthase T-786c mutation, a treatable etiology of Prinzmetal's angina. Transl Res. 2013;162(1):64-6.
http://dx.doi.org/10.1016/j.trsl.2013.03.003 DOI: https://doi.org/10.1016/j.trsl.2013.03.003
PMid:23567331
Giorgio Ghilardi, Maria Luisa Biondi, Marco DeMonti, et al. Independent Risk Factor for Moderate to Severe Internal Carotid Artery Stenosis:T786 Mutation of the Endothelial Nitric Oxide Synthase Gene. Clinical Chemistry. 2002;48:989-993. DOI: https://doi.org/10.1093/clinchem/48.7.989
PMid:12089165
Toda N, Toda H. Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine. Eur J Pharmacol 2010; 649(1-3):1-13.
http://dx.doi.org/10.1016/j.ejphar.2010.09.042 DOI: https://doi.org/10.1016/j.ejphar.2010.09.042
PMid:20868673
Gian Paolo Rossi, Giuseppe Maiolino, Mario Zanchetta, et al.The T-786C Endothelial Nitric Oxide Synthase Genotype Predicts Cardiovascular Mortality in High-Risk Patients. J Am Coll Cardiol. 2006;48:1166–74.
http://dx.doi.org/10.1016/j.jacc.2006.05.046 DOI: https://doi.org/10.1016/j.jacc.2006.05.046
PMid:16979000
Maria Satra, Maria Samara, Greta Wosniak, et al. Sequence Variations in the FII, FV, F13A1, FGB and PAI-1 Genes are Associated with Differences in Myocardial Perfusion. Pharmacogenomics. 2011;12(2):195-203.
http://dx.doi.org/10.2217/pgs.10.180 DOI: https://doi.org/10.2217/pgs.10.180
PMid:21332313
Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90(5):1747-50. DOI: https://doi.org/10.1182/blood.V90.5.1747
PMid:9292507
Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92(7):2353-8. DOI: https://doi.org/10.1182/blood.V92.7.2353.2353_2353_2358
PMid:9746774
Wagh SB, Anadure R, Dutta V, et al. Isolated protein S deficiency presenting as catastrophic systemic arterial and subsequently venous thrombosis. Australas Med J. 2012;5(8):424-8.
http://dx.doi.org/10.4066/AMJ.2012.1309 DOI: https://doi.org/10.4066/AMJ.2012.1309
PMid:23024716 PMCid:PMC3442186
Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation. 2008;118(16):1659-67.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.780759 DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.780759
PMid:18824642
Auro K1, Alanne M, Kristiansson K, et al. Combined effects of thrombosis pathway gene variants predict cardiovascular events. PLoS Genet. 2007;3(7):e120.
http://dx.doi.org/10.1371/journal.pgen.0030120 DOI: https://doi.org/10.1371/journal.pgen.0030120
PMid:17677000 PMCid:PMC1934395
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0